文献速递中医内科中药与中成药合理使用

平康颗粒治疗Graves甲亢的多中心随机双盲安慰剂对照试验

Clinical efficacy of Chinese herbal medicine formula for Graves' hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial.
PubMed 文献 · J Ethnopharmacol · 2024-11-15

本研究为多中心随机双盲安慰剂对照试验,纳入186例Graves甲亢患者,比较甲巯咪唑联合平康颗粒、单用甲巯咪唑及单用平康颗粒治疗12周的疗效。结果显示三种方案均显著降低FT3和FT4,甲巯咪唑联合平康颗粒显著降低TRAb,平康颗粒单药改善甲亢相关症状及ThyPRO39评分。

要点

  • 甲巯咪唑联合平康颗粒可显著降低Graves甲亢患者血清TRAb水平。
  • 平康颗粒单药可改善甲亢症状、眼症、疲劳、认知、抑郁及易感性评分。
  • 三种方案安全性相似,未报告严重不良事件。

核心结论

  • 平康颗粒联合甲巯咪唑可显著降低Graves甲亢患者血清TRAb水平。
  • 平康颗粒单药或联合甲巯咪唑均能显著降低FT3、FT4及STA-PSV,并改善ThyPRO39评分。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验,共纳入186例Graves甲亢患者,来自5个医疗中心。
  • 患者按1:1:1随机分为三组:A组(甲巯咪唑+平康颗粒安慰剂)、B组(甲巯咪唑+平康颗粒)、C组(甲巯咪唑安慰剂+平康颗粒),疗程12周。
  • 全分析集150例,A、B、C组分别为48、50、52例。

主要发现

  • 终点时三组血清FT3水平较基线显著降低(A组p=0.0027;B组p<0.0001;C组p=0.0028)。
  • 终点时三组血清FT4水平较基线显著降低(A组p<0.0001;B组p<0.0001;C组p<0.0001)。
  • B组(甲巯咪唑+平康颗粒)血清TRAb水平显著降低(p=0.0014)。
  • A组第12周甲状腺体积较基线显著增大(p=0.0370),第4周(p=0.7485)和第12周(p=0.1333)组间甲状腺体积无统计学差异。
  • B组第4周STA-PSV显著高于A组(p=0.0409);A组(p<0.0001)和C组(p=0.0025)第4周STA-PSV较基线显著降低;三组第12周STA-PSV均较基线显著降低(A组p=0.0095;B组p=0.0138;C组p=0.0423)。

临床怎么用

  • 对于Graves甲亢患者,可考虑在甲巯咪唑基础上联用平康颗粒以降低TRAb水平。
  • 平康颗粒单药或联合甲巯咪唑可改善甲亢相关症状及甲状腺相关生活质量评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: According to the theory of traditional Chinese medicine, Graves' disease (GD) is called 'Ying Bing', which is a kind of goiter. Haizao Yuhu decoction, originated from the medical book of the Ming Dynasty 'Waikezhengzong', is a classic Chinese herbal formula for the treatment of 'Ying Bing' for more than 400 years. Pingkang granules, modified from the Chinese herbal formula Haizao Yuhu decoction specialized in GD, has shown effectiveness in several single-centre studies. However, high-quality clinical evidence for the management of GD using Pingkang granules remains insufficient. AIM OF THE STUDY: To obtain high-quality medical evidence for the treatment of GD with Pingkang granules through randomized controlled clinical trial. MATERIALS AND METHODS: A multicentre, randomized, double-blinded, placebo-controlled clinical trial was designed. A total of 186 patients with Graves' hyperthyroidism from five medical centers were randomly assigned to receive methimazole [MMI] and Pingkang granules placebo (group A), MMI and Pingkang granules (group B), or MMI placebo and Pingkang granules (group C) in a 1:1:1 ratio for 12 weeks. The primary clinical outcomes were serum free triiodothyronine (FT3) and free thyroxine (FT4) levels from baseline until the end of the research. Secondary clinical outcomes included serum thyrotrophin receptor antibody (TRAb) levels at 4- and 12-weeks post-intervention, thyroid volume, peak systolic velocity of the superior thyroid artery (STA-PSV), 39-item version of Thyroid-Related Patient-Reported Outcome (ThyPRO39) scores, and safety assessment included blood routine, liver and kidney function tests from baseline to the endpoint. RESULTS: 150 patients were included in the full analysis set for efficacy analysis, including 48, 50, and 52 in groups A, B, and C, respectively. At the endpoint, three regimens significantly reduced serum FT3 levels (group A, p=0.0027; group B, p < 0.0001; group C, p=0.0028) and FT4 levels (group A, p < 0.0001; group B, p < 0.0001; group C, p < 0.0001), and the combination of MMI and Pingkang granules markedly reduced serum TRAb levels (p = 0.0014). The thyroid volume in group A was significantly larger than that at baseline at week 12 (p=0.0370), and there were no statistically significant differences in the thyroid volume among groups at week 4 (p=0.7485) and 12 (p=0.1333). STA-PSV values in group B were significantly higher than those in group A at week 4 (p=0.0409). The STA-PSV levels in groups A (p < 0.0001) and C (p=0.0025) were significantly lower than those at baseline at week 4, and STA-PSV levels in all groups were significantly lower than those at baseline at week 12 (group A, p=0.0095; group B, p=0.0138; group C, p=0.0423). Pingkang granule monotherapy significantly ameliorated symptoms related to hyperthyroidism (p < 0.0001), eye (p=0.0490), tiredness (p < 0.0001), cognition (p < 0.0001), depression (p=0.0478), and susceptibility (p=0.0052). No severe adverse events were reported in either group or three regimens showed similar safety. CONCLUSIONS: Pingkang granules significantly reduced serum FT3, FT4 and STA-PSV levels, improved ThyPRO39 scores, and lowered serum TRAb levels when combined with MMI in patients with Grave's hyperthyroidism.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Gan D, Gao TS, Ma L, et al. Clinical efficacy of Chinese herbal medicine formula for Graves' hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial. J Ethnopharmacol. 2024. PMID: 39550016. doi:10.1016/j.jep.2024.119106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。